Trial abstract · §3
ORFO-PH2-T2D — results
Primary endpoint, absolute and relative effect where derivable, and harms as reported.
§3Results
§3.1Primary endpoint
Table 3. Primary endpoint as reported.
| Endpoint | Result as reported | Certainty |
|---|---|---|
| Change in glycated haemoglobin from baseline to week 26 | Reduction of up to 2.1 percentage points versus 0.4 with placebo | Moderate |
| Reproduced from the published report. Where the report states a confidence interval the Institute reproduces it; where it does not, none is constructed. | ||
§3.2Endpoint hierarchy
§3.3Harms as reported
Table 5. Adverse events for Orforglipron from the safety tables the Institute holds for this compound. Where a row names a different trial as its source, the figure is from that trial and not from this one.
| Event | Active, % | Comparator, % | Source trial |
|---|---|---|---|
| Nausea | 44.0 | 9.0 | Phase 2 obesity (45 mg) |
| Vomiting | 25.0 | 2.0 | Phase 2 obesity |
| Constipation | 21.0 | 9.0 | Phase 2 obesity |
| Diarrhoea | 24.0 | 12.0 | Phase 2 obesity |
| Discontinuation for adverse events | 10.0 | 2.0 | Phase 2 obesity |
| Hepatic enzyme elevation | — | — | Monitored; no consistent signal reported in phase 2 |
Compound Evidence Institute · CEI-TR-0044/3 · https://compoundevidence.com/trials/orfo-ph2-t2d/results/ · retrieved 30 July 2026